BERKELEY, CA (UroToday.com) - Striant ® sustained-release (SR) testosterone buccal system (The Urology Company) is a mucoadhesive tablet that adheres to the gum surface in the mouth providing controlled- and sustained-release of testosterone over a 12-h dosing period.
Striant SR is indicated for testosterone replacement therapy (TRT) for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.(1)
Striant SR was the first buccal system for TRT and remains the only product on the market delivering testosterone by this unique route. The pharmacokinetics, efficacy and safety data obtained from clinical trials were examined in previous reviews of Striant SR around the time of the product launch.(2,3) This review aims to re-evaluate that data considering developments in treatment guidelines and the experience gained from >7 years of prescribing and access to previously unpublished results from two long-term safety studies...View or save the full text Mini Review as a .pdf file
| What’s known on the subject? and What does the study add? Striant® SR is the only available buccal delivery system for testosterone replacement therapy. Previous pharmacokinetic studies have shown that Striant SR effectively produces physiological serum testosterone levels in hypogonadal men. Efficacy and safety data from previously unpublished studies over 2 years of continuous use indicate that Striant SR is effective long term in maintaining serum testosterone within a physiological range, is well tolerated and has a high level of patient acceptance. |
Wallace W. Dinsmore and Michael G. Wyllie*
Royal Victoria Hospital, Belfast and * Plethora Solutions Holdings Plc., London, UK
More BJUI Mini Reviews and Archives
